Search - tctmd.com

Displaying 181 - 200 of 331

Sort: Relevancy | Date

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

February 24, 2020

Safer, Quicker Discharge With Protocols for Enhanced Recovery After Surgery

News Conference News STS 2020

Safer, Quicker Discharge With Protocols for Enhanced Recovery After Surgery

Yael L. Maxwell

February 07, 2020

ACS After TAVR a Unique Condition With Poor Prognosis

News Daily News

ACS After TAVR a Unique Condition With Poor Prognosis

February 05, 2020

Embolization Coils May Be an Option for Leaks After LAA Occlusion

News Daily News

Embolization Coils May Be an Option for Leaks After LAA Occlusion

January 15, 2020

The Biggest News of 2019: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2019: TCTMD’s Top 10

January 01, 2020

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

News Daily News

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

December 19, 2019

News Daily News

Routine Anticoagulation Seems Warranted After TMVR: Review

December 04, 2019

Long-term Watchman Data Reassure: CAP and CAP2 Registries

News Daily News

Long-term Watchman Data Reassure: CAP and CAP2 Registries

Michael O'Riordan

December 02, 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Stroke Prevention

Presentation Controversies and Advances 2019

Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Stroke Prevention

Presenter: Tarun Chakravarty

November 15, 2019

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

News Daily News

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

November 01, 2019

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

News Daily News

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

October 18, 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

News Conference News TCT 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

October 04, 2019

Mitral Valvuloplasty State of the Art: Indications, Devices, Technique, and Outcomes

Presentation TCT 2019

Mitral Valvuloplasty State of the Art: Indications, Devices, Technique, and Outcomes

Presenter: Habib Gamra

September 28, 2019

Nonrheumatic MAC-Related Mitral Stenosis and Balloon Valvuloplasty

Presentation TCT 2019

Nonrheumatic MAC-Related Mitral Stenosis and Balloon Valvuloplasty

Presenter: Igor Palacios

September 28, 2019

MAC Types and Clinical Implications

Presentation TCT 2019

MAC Types and Clinical Implications

Presenter: Philipp Blanke

September 28, 2019

Transcatheter Mitral Valve Repair and Replacement Clinical Trial Designs After COAPT and MITRA-FR

Presentation TCT 2019

Transcatheter Mitral Valve Repair and Replacement Clinical Trial Designs After COAPT and MITRA-FR

Presenter: Gregg Stone

September 28, 2019

Antiplatelet and Anticoagulation After TMVR and TAVR: Considerations and Recommendations

Presentation TCT 2019

Antiplatelet and Anticoagulation After TMVR and TAVR: Considerations and Recommendations

Presenter: Robert Bonow

September 28, 2019

Combination Valve Treatments (MR and TR/MR and AS): Rationale, Sequence, and Results

Presentation TCT 2019

Combination Valve Treatments (MR and TR/MR and AS): Rationale, Sequence, and Results

Presenter: Georg Nickenig

September 28, 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.